ArticleJournal of cancer research and clinical oncology2024

PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data.

Yihui Ge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.